DATANG POWER (00991) has completed the issuance of 2 billion yuan worth of short-term financing bonds.
Datang Power Generation (00991) announced that the company has recently completed the issuance of the "Datang International Power Generation Co., Ltd. 2026 Third Tranche of Ultra Short-term Financing Bonds" ("this tranche of ultra-short-term financing bonds"). This tranche of ultra-short-term financing bonds has an issuance amount of RMB 2 billion, a maturity of 120 days, a face value of RMB 100 yuan, an issuance coupon rate of 1.48%, and an interest start date of March 18, 2026.
DATANG POWER (00991) announced that the company has recently completed the issuance of the "Datang International Power Co., Ltd. 2026 Third Tranche Super Short-term Financing Notes" ("this tranche of super short-term financing notes"). The issuance amount of this tranche of super short-term financing notes is RMB 2 billion, with a maturity of 120 days, a unit face value of RMB 100, an issuance coupon rate of 1.48%, and an interest start date of March 18, 2026.
Related Articles

BEISEN HOLDING (09669) spent HK$363,600 on March 18th to buy back 81,200 shares.

LAEKNA-B is expected to achieve revenues of approximately 107 million yuan in 2025, with a year-on-year increase in research and development expenses of 16.17%.

TRANSTHERA-B (02617): The first patient in Phase II clinical trial of combination of Enzalutamide and Fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer patients who have failed prior treatments has completed dosing.
BEISEN HOLDING (09669) spent HK$363,600 on March 18th to buy back 81,200 shares.

LAEKNA-B is expected to achieve revenues of approximately 107 million yuan in 2025, with a year-on-year increase in research and development expenses of 16.17%.

TRANSTHERA-B (02617): The first patient in Phase II clinical trial of combination of Enzalutamide and Fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer patients who have failed prior treatments has completed dosing.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


